cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2021-36-3-45-50cardiotomsk-1243Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESКлинико-патогенетические особенности хронической сердечной недостаточности с промежуточной фракцией выбросаClinical and pathogenetic features of chronic heart failure with mid-range ejection fractionhttps://orcid.org/0000-0002-9521-4030ШляхтинаН. В.ShlyakhtinaN. V.

Шляхтина Наталья Викторовна - кандидат медицинских наук, доцент, Институт медицины и психологии В. Зельмана, Новосибирский НИГУ; врач, Государственная Новосибирская ОКБ.

630090, Новосибирск, ул. Пирогова, 1; 630087, Новосибирск, ул. Немировича-Данченко, 130

Natalya V. Shlyakhtina, Cand. Sci. (Med.), Associate Professor, V. Zelman Institute for Medicine and Psychology, Novosibirsk SU; Physician, State Novosibirsk RCH.

1, Pirogova str., Novosibirsk, 630090; 130, Nemirovicha-Danchenko str., Novosibirsk, 630087

natashanvkz@mail.ruhttps://orcid.org/0000-0001-9218-9979АнтоненокЕ. А.AntonenokE. A.

Антоненок Екатерина Александровна - ординатор второго года по специальности Кардиология.

630087, Новосибирск, ул. Немировича-Данченко, 130

Ekaterina A. Antonenok, Second-Year Medical Resident in Cardiology.

1, Pirogova str., Novosibirsk, 630090

katya.antonenok@mail.ruhttps://orcid.org/0000-0002-8353-052XГаланцевА. О.GalantsevA. O.

Галанцев Александр Олегович, ординатор первого года по специальности Кардиология.

630087, Новосибирск, ул. Немировича-Данченко, 130

Alexander O. Galantsev, First-Year Medical Resident in Cardiology.

1, Pirogova str., Novosibirsk, 630090

a.galantsev@g.nsu.ruИнститут медицины и психологии В. Зельмана, Новосибирский национальный исследовательский государственный университет; Государственная Новосибирская областная клиническая больницаРоссияV. Zelman Institute for Medicine and Psychology, Novosibirsk State University; State Novosibirsk Regional Clinical HospitalRussian FederationИнститут медицины и психологии В. Зельмана, Новосибирский национальный исследовательский государственный университетРоссияV. Zelman Institute for Medicine and Psychology, Novosibirsk State UniversityRussian Federation2021061020213634550Copyright © Шляхтина Н.В., Антоненок Е.А., Галанцев А.О., 20212021Шляхтина Н.В., Антоненок Е.А., Галанцев А.О.Shlyakhtina N.V., Antonenok E.A., Galantsev A.O.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/1243

недостаточности с промежуточной фракцией выброса (ХСНпрФВ). Анализируются особенности патогенеза, клинического течения ХСНпрФВ. Освещаются современные подходы к терапии ХСНпрФВ.

The literature review is devoted to a new class of chronic heart failure, namely: chronic heart failure with mid-range ejection fraction (HFmrEF). In this article, we aim to clarify the existing literature on the clinical characteristics and pathophysiology of this newly-defined group of patients. Modern approaches to the therapy of HFmrEF are analyzed.

хроническая сердечная недостаточностьфракция выбросалевый желудочекдиастолическая дисфункцияchronic heart failureleft ventricularejection fractiondiastolic dysfunctionReferencesАгеев Ф.Т., Овчинников А.Г. Сердечная недостаточность с промежуточной фракцией выброса левого желудочка: существует ли клиническая необходимость выделения ее в отдельную группу? Кардиология. 2018;58(12S):4–10. DOI: 10.18087/cardio.2609.Ageev F.T., Ovchinnikov A.G. Heart failure with mid-range ejection fraction: Аre there clinical reasons in introduction of this new group as a distinct entity? Kardiologiia. 2018;58(12S):4–10 (In Russ.). DOI: 10.18087/ cardio.2609.Hsu J.J., Ziaeian B., Fonarow G.C. Heart failure with mid-range (borderline) ejection fraction: Clinical implications and future direc-tions. JACC Heart Fail. 2017;5(11):763–771. DOI: 10.1016/j.jchf.2017.06.013.Hsu J.J., Ziaeian B., Fonarow G.C. Heart failure with mid-range (borderline) ejection fraction: Clinical implications and future directions. JACC Heart Fail. 2017;5(11):763–771. DOI: 10.1016/j.jchf.2017.06.013.Ibrahim N.E., Song Y., Cannon C.P., Doros G., Russo P., Ponirakis A. et al. Heart failure with mid-range ejection fraction: Characterization of patients from the PINNACLE registry(R). ESC Heart Fail. 2019;6(4):784–792.Ibrahim N.E., Song Y., Cannon C.P., Doros G., Russo P., Ponirakis A. et al. Heart failure with mid-range ejection fraction: Characterization of patients from the PINNACLE registry(R). ESC Heart Fail. 2019;6(4):784–792.Srivastava P.K., Hsu J.J., Ziaeian B., Fonarow G.C. Heart failure with mid-range ejection fraction. Curr. Heart Fail. Rep. 2020;17(1):1–8. DOI: 10.1007/s11897-019-00451-0.Srivastava P.K., Hsu J.J., Ziaeian B., Fonarow G.C. Heart failure with mid-range ejection fraction. Curr. Heart Fail. Rep. 2020;17(1):1–8. DOI: 10.1007/s11897-019-00451-0.Lauritsen J., Gustafsson F., Abdulla J. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: A systematic review and meta-analysis. ESC HEART FAILURE. ESC Heart Fail. 2018;5(4):685–694. DOI: 10.1002/ehf2.12283.Lauritsen J., Gustafsson F., Abdulla J. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: A systematic review and meta-analysis. ESC HEART FAILURE. ESC Heart Fail. 2018;5(4):685–694. DOI: 10.1002/ehf2.12283.Tsuji K., Sakata Y., Nochioka K., Miura M., Yamauchi T., Onose T. et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 study. Eur. J. Heart Fail. 2017;19(10):1258–1269. DOI: 10.1002/ejhf.807.Tsuji K., Sakata Y., Nochioka K., Miura M., Yamauchi T., Onose T. et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 study. Eur. J. Heart Fail. 2017;19(10):1258–1269. DOI: 10.1002/ejhf.807.Boulet J., Massie E., Rouleau J.L. Heart Failure with mid-range ejection fraction – what is it, if аnything? Can. J. Cardiol. 2020;37(4):585–594. DOI: 10.1016/j.cjca.2020.11.013.Boulet J., Massie E., Rouleau J.L. Heart Failure with mid-range ejection fraction – what is it, if аnything? Can. J. Cardiol. 2020;37(4):585–594. DOI: 10.1016/j.cjca.2020.11.013.Savarese G., Vasko P., Jonsson Å., Edner M., Dahlström U., Lund L.H. The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure. Ups. J. Med. Sci. 2019;124(1):65–69. DOI: 10.1080/03009734.2018.1490831.Savarese G., Vasko P., Jonsson Å., Edner M., Dahlström U., Lund L.H. The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure. Ups. J. Med. Sci. 2019;124(1):65–69. DOI: 10.1080/03009734.2018.1490831.Streng K.W., Nauta J.F., Hillege H.L., Anker S.D., Cleland J.G., Dickstein K. et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int. J. Cardiol. 2018;271:132–139. DOI: 10.1016/j.ijcard.2018.04.001.Streng K.W., Nauta J.F., Hillege H.L., Anker S.D., Cleland J.G., Dickstein K. et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int. J. Cardiol. 2018;271:132–139. DOI: 10.1016/j.ijcard.2018.04.001.Mesquita E.T., dos Santos Barbetta L.M., de Oliveira Correia E.T. Heart failure with mid-range ejection fraction – state of the art. Arq. Bras. Cardiol. 2019;112(6):784–790. DOI: 10.5935/abc.20190079.Mesquita E.T., dos Santos Barbetta L.M., de Oliveira Correia E.T. Heart failure with mid-range ejection fraction – state of the art. Arq. Bras. Cardiol. 2019;112(6):784–790. DOI: 10.5935/abc.20190079.Chioncel O., Lainscak M., Seferovic P.M., Anker S.D., Crespo-Leiro M.G., Harjola V.P. et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur. J. Heart Fail. 2017;19(12):1574–1585. DOI: 10.1002/ejhf.813.Chioncel O., Lainscak M., Seferovic P.M., Anker S.D., Crespo Leiro M.G., Harjola V.P. et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure LongTerm Registry. Eur. J. Heart Fail. 2017;19(12):1574–1585. DOI: 10.1002/ejhf.813.Cheng R.K., Cox M., Neely M.L., Heidenreich P.A., Bhatt D.L., Eapen Z.J. et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am. Heart J. 2014;168(5):721–730. DOI: 10.1016/j.ahj.2014.07.008.Cheng R.K., Cox M., Neely M.L., Heidenreich P.A., Bhatt D.L., Eapen Z.J. et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am. Heart J. 2014;168(5):721–730. DOI: 10.1016/j.ahj.2014.07.008.Gomez-Otero I., Ferrero-Gregori A., Varela Roman A., Seijas Amigo J., Pascual-Figal D.A., Delgado Jimenez J. Mid-range ejection fraction does not permit risk stratification among patients hospitalized forheart failure. Rev. Esp. Cardiol. (Engl. Ed.). 2017;70(5):338–346. DOI: 10.1016/j.rec.2016.11.016.Gomez-Otero I., Ferrero-Gregori A., Varela Roman A., Seijas Amigo J., Pascual-Figal D.A., Delgado Jimenez J. Mid-range ejection fraction does not permit risk stratification among patients hospitalized forheart failure. Rev. Esp. Cardiol. (Engl. Ed.). 2017;70(5):338–346. DOI: 10.1016/j.rec.2016.11.016.Rickenbacher P., Kaufmann B.A., Maeder M.T., Bernheim A., Goetschalckx K., Pfister O. et al. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the trial of intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). Eur. J. Heart Fail. 2017;19(12):1586–1596. DOI: 10.1002/ejhf.798.Rickenbacher P., Kaufmann B.A., Maeder M.T., Bernheim A., Goetschalckx K., Pfister O. et al. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the trial of intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). Eur. J. Heart Fail. 2017;19(12):1586–1596. DOI: 10.1002/ejhf.798.Gohar A., Chong J.P.C., Liew O.W., den Ruijter H., deKleijn D.P.V., Sim D. et al. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart fail ure and a preserved vs. reduced ejection fraction. Eur. J. Heart Fail. 2017;19(12):1638–1647. DOI: 10.1002/ejhf.911.Gohar A., Chong J.P.C., Liew O.W., den Ruijter H., de Kleijn D.P.V., Sim D. et al. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart fail ure and a preserved vs. reduced ejection fraction. Eur. J. Heart Fail. 2017;19(12):1638–1647. DOI: 10.1002/ejhf.911.Tromp J., Khan M.A.F., Mentz R.J., O’Connor C.M., Metra M., Dittrich H.C. et al. Biomarker profiles of acute heart failure patients with a mid-range ejection fraction. JACC Heart Fail. 2017;5(7):507–517. DOI: 10.1016/j.jchf.2017.04.007.Tromp J., Khan M.A.F., Mentz R.J., O’Connor C.M., Metra M., Dittrich H.C. et al. Biomarker profiles of acute heart failure patients with a mid-range ejection fraction. JACC Heart Fail. 2017;5(7):507–517. DOI: 10.1016/j.jchf.2017.04.007.Topilsky Y., Rozenbaum Z., Khoury S., Pressman G.S., Gura Y., Sherez J. et al. Mechanisms of effort intolerance in patients with heart failure borderline ejection fraction. Am. J. Cardiol. 2017;119(3):416–442. DOI: 10.1016/j.amjcard.2016.10.026.Topilsky Y., Rozenbaum Z., Khoury S., Pressman G.S., Gura Y., Sherez J. et al. Mechanisms of effort intolerance in patients with heart failure borderline ejection fraction. Am. J. Cardiol. 2017;119(3):416–442. DOI: 10.1016/j.amjcard.2016.10.026.Pugliese N.R., Fabiani I., Santini C., Rovai I., Pedrinelli R., Natali A. et al. Value of combined cardiopulmonary and echocardiography stress test to characterize the haemodynamic and metabolic responses of patients with heart failure and mid-range ejection fraction. Eur. Heart J. Cardiovasc. Imaging. 2019;20(7):828–836. DOI: 10.1093/ehjci/jez014.Pugliese N.R., Fabiani I., Santini C., Rovai I., Pedrinelli R., Natali A. et al. Value of combined cardiopulmonary and echocardiography stress test to characterize the haemodynamic and metabolic responses of patients with heart failure and mid-range ejection fraction. Eur. Heart J. Cardiovasc. Imaging. 2019;20(7):828–836. DOI: 10.1093/ehjci/jez014.Rastogi A., Novak E., Platts A.E., Mann D.L. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction: Heart failure with mid-range ejection fraction. Eur. J. Heart Fail. 2017;19(12):1597–1605. DOI: 10.1002/ejhf.879.Rastogi A., Novak E., Platts A.E., Mann D.L. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction: Heart failure with mid-range ejection fraction. Eur. J. Heart Fail. 2017;19(12):1597–1605. DOI: 10.1002/ejhf.879.Branca L., Sbolli M., Fudim M. Heart failure with mid-range ejection fraction: Pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines. ESC Heart Fail. 2020;7(2):381–399. DOI: 10.1002/ehf2.12586.Branca L., Sbolli M., Fudim M. Heart failure with mid-range ejection fraction: Pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines. ESC Heart Fail. 2020;7(2):381–399. DOI: 10.1002/ehf2.12586.Vatutin N., Shevelok A., Venzheha V. Position of patients with midrange ejection fraction in the general chronic heart failure population. The Russian Archives of Internal Medicine. 2021;11(2):111-121. DOI: 10.20514/2226-6704-2021-11-2-111-121.Vatutin N., Shevelok A., Venzheha V. Position of patients with midrange ejection fraction in the general chronic heart failure population. The Russian Archives of Internal Medicine. 2021;11(2):111–121. DOI: 10.20514/2226-6704-2021-11-2-111-121.Cleland J.G.F., Bunting K.V., Flather M.D., Altman D.G., Holmes J., Coats A.J.S et al. Beta-blockers for heart failure with reduced, midrange, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur. Heart J. 2018;39(1):26–35. DOI: 10.1093/eurheartj/ehx564.Cleland J.G.F., Bunting K.V., Flather M.D., Altman D.G., Holmes J., Coats A.J.S et al. Beta-blockers for heart failure with reduced, midrange, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur. Heart J. 2018;39(1):26–35. DOI: 10.1093/eurheartj/ehx564.Lund L.H., Claggett B., Liu J. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur. J. Heart Fail. 2018;20(8):1230–1239. DOI: 10.1002/ejhf.1149.Lund L.H., Claggett B., Liu J. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur. J. Heart Fail. 2018;20(8):1230–1239. DOI: 10.1002/ejhf.1149.Riello R.J., Pitt B. ARNI and MRA Combination in PARAGON-HF: Odd сouple or dynamic duo? JACC Heart Fail. 2021;9(1):25–27. DOI: 10.1016/j.jchf.2020.10.005.Riello R.J., Pitt B. ARNI and MRA Combination in PARAGON-HF: Odd сouple or dynamic duo? JACC Heart Fail. 2021;9(1):25–27. DOI: 10.1016/j.jchf.2020.10.005.Pitt B., Pfeffer M.A., Assmann S.F., Boineau R., Anand I.S., Claggett B. et al. Spironolactone for heart failure with preserved ejection frac tion. N. Engl. J. Med. 2014;370(15):1383–1392. DOI: 10.1056/NEJMoa1313731.Pitt B., Pfeffer M.A., Assmann S.F., Boineau R., Anand I.S., Claggett B. et al. Spironolactone for heart failure with preserved ejection frac tion. N. Engl. J. Med. 2014;370(15):1383–1392. DOI: 10.1056/NEJMoa1313731.Агеев Ф.Т. Современная концепция диастолической сердечной недостаточности. Кардиоваскулярная терапия и профилактика. 2010;9(7):97–104.Ageev F.T. Modern concept of diastolic heart failure. Cardiovascular Therapy and Prevention. 2010;9(7):97–104 (In Russ.).Дуболазова Ю.В., Драпкина О.М. Применения галектина-3 и NTproBNP в качестве биомаркеров декомпенсированной сердечной недостаточности. Российский кардиологический журнал. 2017;(1):95–101. DOI: 10.15829/1560-4071-2017-1-95-101.Dubolazova Yu.V., Drapkina O.M. Galectin-3 and NT-proBNP as biomarcers of heart failure decompensation. Russian Journal of Cardiology. 2017;(1):95–101 (In Russ.). DOI: 10.15829/1560-4071-2017-1-95-101.Подзолков В.И., Драгомирецкая Н.А., Столбова С.К., Русинов И.С. Ассоциации уровней NT-proBNP и гепсидина с клинико-лабораторными параметрами у больных хронической сердечной недостаточностью с разной степенью систолической дисфункции левого желудочка. Кардиоваскулярная терапия и профилактика. 2020;19(4):2587. DOI: 10.15829/1728-88002020-2587.Podzolkov V.I., Dragomiretskaya N.A., Stolbova S.K., Rusinov I.S. Associations of NT-proBNP and hepcidin levels with clinical and laboratory parameters in patients with heart failure with various severity of left ventricular systolic dysfunction. Cardiovascular Therapy and Prevention. 2020;19(4):2587 (In Russ.). DOI: 10.15829/1728-8800-2020-2587.

The authors declare that there are no conflicts of interest present.